HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Immunotherapy for fungal infections.

AbstractOpportunistic fungal infections are major causes of morbidity and mortality among immunocompromised individuals. Fungi have evolved complex and coordinated mechanisms to survive in the environment and in the mammalian host. Fungi must adapt to "stressors" in the host (including scarcity of nutrients, pH, and reactive oxygen and nitrogen intermediates) in addition to evading host immunity. Knowledge of the immunopathogenesis of fungal infections has paved the way to promising strategies for immunotherapy. These include strategies that increase phagocyte number, activate innate host defense pathways in phagocytes and dendritic cells, and stimulate antigen-specific immunity (e.g., vaccines). Immunotherapy must be tailored to specific immunocompromised states. Challenges exist in bringing promising immunotherapies from the laboratory to clinical trials.
AuthorsBrahm H Segal, June Kwon-Chung, Thomas J Walsh, Bruce S Klein, Minoo Battiwalla, Nikolaos G Almyroudis, Steven M Holland, Luigina Romani (Affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. brahm.segal at roswellpark.org)
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 42 Issue 4 Pg. 507-15 (Feb 15 2006) ISSN: 1537-6591 [Electronic] United States
PMID16421795 (Publication Type: Journal Article, Review)
Chemical References
  • Adjuvants, Immunologic
  • Antibodies
  • Colony-Stimulating Factors
  • Fungal Vaccines
  • Interferon-gamma, Recombinant
  • Serum Amyloid P-Component
  • Toll-Like Receptors
  • PTX3 protein
  • C-Reactive Protein
Topics
  • Adjuvants, Immunologic (therapeutic use)
  • Antibodies (therapeutic use)
  • C-Reactive Protein (immunology)
  • Clinical Trials as Topic
  • Colony-Stimulating Factors (therapeutic use)
  • Fungal Vaccines (administration & dosage)
  • Humans
  • Immunocompromised Host (immunology)
  • Immunotherapy (methods)
  • Interferon-gamma, Recombinant (therapeutic use)
  • Leukocyte Transfusion
  • Mycoses (complications, immunology, therapy)
  • Neutropenia (complications, therapy)
  • Opportunistic Infections (immunology)
  • Serum Amyloid P-Component (immunology)
  • Toll-Like Receptors (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD